- Home
- NEGG vs EPIX Comparison
NEGG vs EPIX Comparison
Compare NEGG & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- EPIX
- Stock Information
- Founded
- NEGG 2001
- EPIX 2009
- Country
- NEGG United States
- EPIX Canada
- Employees
- NEGG N/A
- EPIX N/A
- Industry
- NEGG Other Specialty Stores
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- EPIX Health Care
- Exchange
- NEGG Nasdaq
- EPIX Nasdaq
- Market Cap
- NEGG 75.6M
- EPIX 71.5M
- IPO Year
- NEGG 2010
- EPIX N/A
- Fundamental
- Price
- NEGG $5.30
- EPIX $1.68
- Analyst Decision
- NEGG
- EPIX Hold
- Analyst Count
- NEGG 0
- EPIX 3
- Target Price
- NEGG N/A
- EPIX $2.00
- AVG Volume (30 Days)
- NEGG 301.4K
- EPIX 138.8K
- Earning Date
- NEGG 04-28-2025
- EPIX 05-08-2025
- Dividend Yield
- NEGG N/A
- EPIX N/A
- EPS Growth
- NEGG N/A
- EPIX N/A
- EPS
- NEGG N/A
- EPIX N/A
- Revenue
- NEGG $1,235,576,000.00
- EPIX N/A
- Revenue This Year
- NEGG N/A
- EPIX N/A
- Revenue Next Year
- NEGG N/A
- EPIX N/A
- P/E Ratio
- NEGG N/A
- EPIX N/A
- Revenue Growth
- NEGG N/A
- EPIX N/A
- 52 Week Low
- NEGG $3.32
- EPIX $1.40
- 52 Week High
- NEGG $26.40
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- NEGG 49.69
- EPIX 51.94
- Support Level
- NEGG $4.82
- EPIX $1.60
- Resistance Level
- NEGG $6.63
- EPIX $1.70
- Average True Range (ATR)
- NEGG 1.07
- EPIX 0.04
- MACD
- NEGG -0.07
- EPIX -0.00
- Stochastic Oscillator
- NEGG 14.39
- EPIX 82.83
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.